Acetylsalicylic acid/dipyridamole

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Rjwilmsi (talk | contribs) at 08:49, 30 January 2017 (Journal cites, added 1 PMID using AWB (12142)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Acetylsalicylic acid/dipyridamole
Combination of
Acetylsalicylic acidAntithrombotic
DipyridamoleAntithrombotic
Clinical data
Trade namesAggrenox, Asasantin
AHFS/Drugs.comUK Drug Information
Routes of
administration
Oral
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)

The combination drug acetylsalicylic acid/dipyridamole (trade names Aggrenox, Asasantin) is a drug combination of:[1]

The combination acts as an extended release formulation and is primarily used for platelet inhibition in patients suffering, or at risk from, acute coronary events and stroke.[3] Its use has been shown to be better than the use of either dipyridamole or aspirin alone.[4]

References

  1. ^ FASS (the Swedish official drug catalog) > Asasantin Last update: 2009–08–17
  2. ^ "Dipyridamole" at Dorland's Medical Dictionary
  3. ^ Malinin, Alex I.; Eisert, Roswith M.; Atar, Dan; Barkagan, Zinoviy; Serebruany, Victor L. (2002). "Aggrenox® (Extended-Release Dipyridamole and Low-Dose Aspirin in Combination): Protecting Platelets from Excessive Activation in Patients with Vascular Events". Heart Drug. 2 (2): 93–104. doi:10.1159/000063427.
  4. ^ Serebruany, Victor L.; Malinin, Alex I.; Sane, David C.; Jilma, Bernd; Takserman, Aviv; Atar, Dan; Hennekens, Charles H. (September 2004). "Magnitude and time course of platelet inhibition with Aggrenox® and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial". European Journal of Pharmacology. 499 (3): 315–324. doi:10.1016/j.ejphar.2004.07.114. PMID 15381054.